Clinical Characteristics and Growth Hormone Treatment in Patients with Prader-Willi Syndrome

Objective: To investigate clinical characteristics and response to growth hormone (GH) treatment in patients with Prader-Willi syndrome (PWS) in Turkey. Methods: The data of 52 PWS patients from ten centers was retrospectively analyzed. A nation-wide, web-based data system was used for data collection. Demographic, clinical, genetic, and laboratory data and follow-up information of the patients were evaluated. Results: The median age of patients at presentation was 1.5 years, and 50% were females. Genetic analysis showed microdeletion in 69.2%, uniparental disomy in 11.5%, imprinting defect in 1.9% and methylation abnormality in 17.3%. Hypotonia (55.7%), feeding difficulties (36.5%) and obesity (30.7%) were the most common complaints. Cryptorchidism and micropenis were present in 69.2% and 15.3% of males, respectively. At presentation, 25% had short stature, 44.2% were obese, 9.6% were overweight and 17.3% were underweight. Median age of obese patients was significantly higher than underweight patients. Central hypothyroidism and adrenal insufficiency were present in 30.7% and 4.7%, respectively. Hypogonadism was present in 75% at normal age of puberty. GH treatment was started in 40% at a mean age of 4.7±2.7 years. After two years of GH treatment, a significant increase in height SDS was observed. However, body mass index (BMI) standard deviation (SDS) remained unchanged. Conclusion: The most frequent complaints were hypotonia and feeding difficulty at first presentation. Obesity was the initial finding in 44.2%. GH treatment was started in less than half of the patients. While GH treatment significantly increased height SDS, BMI SDS remained unchanged, possibly due to the relatively older age at GH start.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Cassidy SB, Schwartz S, Miller JL, Driscoll DJ. Prader-Willi syndrome. Genet Med. 2012;14:10-26. Epub 2011 Sep 26
2. Vogels A, Vand Den Ende J, Keymolen K, Mortier G, Devriendt K, Legius E, Fryns JP. Minimum prevalence, birth incidence and cause of death for Prader-Willi syndrome in Flanders. Eur J Hum Genet 2004;12:238- 240.
3. Butler MG. Prader-Willi syndrome: Current understanding of cause and diagnosis. Am J Med Genet 1990;35:319-332.
4. Miller JL, Lynn CH, Driscoll DC, Goldstone AP, Gold JA, Kimonis V, Dykens E, Butler MG, Shuster JJ, Driscol DJ. Nutritional phases in Prader-Willi syndrome. Am J Med Genet Part A 2011;155:1040-1049. Epub 2011 Apr 4
5. Swaab D. Prader-Willi syndrome and the hypothalamus. Acta Paediatr 1997;86:50-54.
6. Burman P, Ritzén EM, Lindgren AC. Endocrine dysfunction in PraderWilli syndrome: a review with special reference to GH. Endoc Rev 2001;22:787-799.
7. Deal CL, Tony M, Hoÿbye C, Allen DB, Tauber M, Christiansen JS;2011 Growth Hormone in Prader Willi Syndrome: Clinical Care Guidelines Workshop Participants. Growth hormone research society workshop summary: Consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J Clin Endocrinol Metab 2013;98:E1072-E1087. Epub 2013 Mar 29
8. Grugni G, Sartorio A, Crinò A. Growth hormone therapy for PraderWilli syndrome: challenges and solutions. Ther Clin Risk Manag 2016;12:873-881.
9. Ranke MB. Towards a consensus on the definition of idiopathic short stature. Horm Res 1996;45(Suppl 2):64-66.
10. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, Flegal KM, Guo SS, Wei R, Mei Z, Curtin LR, Roche AF, Johnson CL. CDC growth charts: United States. Adv Data 2000;8:1-27.
11. Neyzi O, Bundak R, Gökçay G, Günöz H, Furman A, Darendeliler F, Bas F. Reference values for weight, height, head circumference, and body mass index in Turkish children. J Clin Res Pediatr Endocrinol 2015;7:280-293.
12. Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. BMC Pediatr 2013;13:59.
13. Persani L, Brabant G, Dattani M, Bonomi M, Feldt-Rasmussen U, Fliers E, Gruters A, Maiter D, Schoenmakers N, van Trotsenburg ASP. 2018 European Thyroid Association (ETA) guidelines on the diagnosis and management of central hypothyroidism. Eur Thyroid J 2018;7:225- 237. Epub 2018 Jul 19
14. Crowley S, Hindmarsh PC, Holownia P, Honour JW, Brook CG. The use of low doses of ACTH in the investigation of adrenal function in man. J Endocrinol 1991;130:475-479.
15. Kaplowitz PB. Delayed puberty. Pediatr Rev 2010;31:189-195.
16. Cinaz P, Yesilkaya E, Onganlar YH, Boyraz M, Bideci A, Camurdan O, Karaoglu AB. Penile anthropometry of normal prepubertal boys in Turkey. Acta Paediatr 2012;101:e33-E36. Epub 2011 Oct 4
17. Bishop N, Arundel P, Clark E, Dimitri P, Farr J, Jones G, Makitie O, Munns CF, Shaw N; International Society of Clinical Densitometry. Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2013 Pediatric Official Positions. J Clin Densitom 2014;17:275-280. Epub 2014 Mar 14
18. Guven B, Can M, Mungan G, Acikgoz S. Reference values for serum levels of insulin-like growth factor 1 (IGF-1) and IGF-binding protein 3 (IGFBP-3) in the West Black Sea region of Turkey. Scand J Clin Lab Invest 2013;73135-73140. Epub 2013 Jan 17
19. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011;128(Suppl 5):S213-S256. Epub 2011 Nov 14
20. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-1495.
21. Holm VA, Cassidy SB, Butler MG, Hanchett JM, Greenswag LR, Whitman BY, Greenberg F. Prader-Willi syndrome: consensus diagnostic criteria. Pediatrics 1993;91:398-402.
22. Gunay-Aygun M, Schwartz S, Heeger S, O’Riordan MA, Cassidy SB. The changing purpose of Prader-Willi syndrome clinical diagnostic criteria and proposed revised criteria. Pediatrics 2001;108:E92.
23. Singh P, Mahmoud R, Gold JA, Miller JL, Roof E, Tamura R, Dykens E, Butler MG, Driscoll DJ, Kimonis V. Multicentre study of maternal and neonatal outcomes in individuals with Prader-Willi syndrome. J Med Genet 2018;55:594-598. Epub 2018 May 18
24. Tuysuz B, Kartal N, Erener-Ercan T, Guclu-Geyik F, Vural M, Perk Y, Ercal D, Erginel-Unaltina N. Prevalence of prader-willi syndrome among infants with hypotonia. J Pediatr 2014;164:1064-1067. Epub 2014 Feb 25
25. Mccandless SE. Clinical reportt health supervision for children with prader-Willi syndrome. Pediatrics 2011;127:195-204. Epub 2010 Dec 27
26. Whittington JE, Butler JV, Holland AJ. Pre-, peri- and postnatal complications in Prader-Willi syndrome in a UK sample. Early Hum Dev 2008;84:331-336. Epub 2007 Oct 4
27. Gross N, Rabinowitz R, Gross-Tsur V, Hirsch HJ, Eldar-Geva T. PraderWilli syndrome can be diagnosed prenatally. Am J Med Genet Part A 2015;167:80-85. Epub 2014 Oct 22
28. Çizmecioğlu FM, Jones JH, Paterson WF, Kherra S, Kourime M, McGowan R, Shaikh MG, Donaldson M. Neonatal features of the Prader-Willi syndrome; the case for making the diagnosis during the first week of life. J Clin Res Pediatr Endocrinol 2018;10:264-273. Epub 2018 Mar 19
29. Goldstone AP. Prader-Willi syndrome: advances in genetics, pathophysiology and treatment. Trends Endocrinol Metab 2004;15:12- 20.
30. Emerick JE, Vogt KS. Endocrine manifestations and management of Prader-Willi syndrome. Int J Pediatr Endocrinol 2013;2013:14.
31. Tauber M, Barbeau C, Jouret B, Pienkowski C, Malzac P, Moncla A, Rochiccioli P. Auxological and endocrine evolution of 28 children with Prader-Willi syndrome: effect of GH therapy in 14 children. Horm Res 2000;53:279-287.
32. Diene G, Mimoun E, Feigerlova E, Caula S, Molinas C, Grandjean H, Tauber M, French Reference Center for PWS. Endocrine disorders in children with Prader-Willi syndrome – data from 142 children of the French database. Horm Res Paediatr 2010;74:121-128. Epub 2010 Apr 15
33. Vaiani E, Herzovich V, Chaler E, Chertkoff L, Rivarola MA, Torrado M, Belgorosky A. Thyroid axis dysfunction in patients with Prader-Willi syndrome during the first 2 years of life. Clin Endocrinol 2010;73:546- 550.
34. De Lind Van Wijngaarden RFA, Otten BJ, Festen DAM, Joosten KFM, De Jong FH, Sweep FCGJ, Hokken-Koelega ACS. High prevalence of central adrenal insufficiency in patients with Prader-Willi syndrome. J Clin Endocrinol Metab 2008;93:1649-1654. Epub 2008 Feb 26
35. Corrias A, Grugni G, Crinò A, Di Candia S, Chiabotto P, Cogliardi A, Chiumello G, De Medici C, Spera S, Gargantini L, Iughetti L, Luce A, Mariani B, Ragusa L, Salvatoni A, Andrulli S, Mussa A, Beccaria L; Study Group for Genetic Obesity of Italian Society of Pediatric Endocrinology and Diabetology (SIEDP/ISPED). Assessment of central adrenal insufficiency in children and adolescents with Prader-Willi syndrome. Clin Endocrinol (Oxf) 2012;76:843-850.
36. Beauloye V, Dhondt K, Buysse W, Nyakasane A, Zech F, De Schepper JVan Aken SV, De Waele K, Craen M, Gies I, Francois I, Beckers D, Desloovere A, Francois G, Cools M. Evaluation of the hypothalamicpituitary-adrenal axis and its relationship with central respiratory dysfunction in children with Prader-Willi syndrome. Orphanet J Rare Dis 2015;10:106.
37. Nyunt O, Cotterill AM, Archbold SM, Wu JY, Leong GM, Verge CF, Crock PA, Ambler GR, Hofman P, Harris M. Normal cortisol response on lowdose synacthen (1 μg) test in children with Prader Willi Syndrome. J Clin Endocrinol Metab 2010;95:E464-E467. Epub 2010 Sep 1
38. Farholt S, Sode-Carlsen R, Christiansen JS, Østergaard JR, Høybye C. Normal cortisol response to high-dose synacthen and insulin tolerance test in children and adults with Prader-Willi syndrome. J Clin Endocrinol Metab 2011;96:E173-E180. Epub 2010 Oct 27
39. Eiholzer U, l’Allemand D, Rousson V, Schlumpf M, Gasser T, Girard J, Grüters A, Simoni M. Hypothalamic and gonadal components of hypogonadism in boys with Prader-Labhart-Willi syndrome. J Clin Endocrinol Metab 2006;91:892-898. Epub 2005 Dec 13
40. Eldar- Geva T, Hirsch H, Benarroch F, Rubinstein O, Gross- Tsur V. Hypogonadism in females with Prader-Willi syndrome from infancy to adulthood: variable combinations of a primary gonadal defect and hypothalamic dysfunction. Eur J Endocrinol 2010;162:377-384. Epub 2009 Nov 27
41. Crinò A, Schiaffini R, Ciampalini P, Spera S, Beccaria L, Benzi F, Bosio L, Corias A, Gargantini L, Salvatoni A, Tonini G, Trifiro G, Livieri C; Genetic Obesity Study Group of Italian Society of Pediatric endocrinology and diabetology (SIEDP). Hypogonadism and pubertal development in Prader-Willi syndrome. Eur J Pediatr 2003;162:327-333. Epub 2003 Feb 27
42. Pellikaan K, Rosenberg AGW, Kattentidt-Mouravieva AA, Kersseboom R, Bos-Roubos AG, Veen-Roelofs JMC, van Wieringen N, Hoekstra FME, van den Berg SAA, van der Lely AJ, de Graaff LCG. Missed diagnoses and health problems in adults with prader-Willi syndrome: recommendations for screening and treatment. J Clin Endocrinol Metab 2020;105:e4671-e4687.
43. Beshyah SA, Freemantle C, Thomas E, Page B, Murphy M, Johnston DG. Comparison of measurements of body composition by total body potassium, bioimpedance analysis, and dual-energy X-ray absorptiometry in hypopituitary adults; before and during growth hormone treatment. Am J Clin Nutr 1995;61:1186-1194.
44. Corrias A, Bellone J, Beccaria L, Bosio L, Trifirò G, Livieri C, Ragusa L, Salvatoni A, Andreo M, Ciampalini P, Tonini G, Crinò A. GH/IGF-I axis in Prader-Willi syndrome: Evaluation of IGF-I levels and of the somatotroph responsiveness to various provocative stimuli. J Endocrinol Invest 2000;23:84-89.
45. Carrel AL, Myers SE, Whitman BY, Allen DB. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study. J Clin Endocrinol Metab 2002;87:1581-1585.
46. Goldstone A, Holland AJ, Hauffa BP, Hokken-Koelaga AC, Taubers M; speakers contributers at the Second Expert Meeting of the Comprehensive Care of Patients with PWS. Recommendations for the diagnosis and management of Prader-Willi syndrome. J Clin Endocrinol Metab 2008;93:4183-4197. Epub 2008 Aug 12
47. Eiholzer U, Nordmann Y, L’Allemand D, Schlumpf M, Schmid S, Kromeyer-Hauschild K. Improving body composition and physical activity in Prader-Willi Syndrome. J Pediatr 2003;142:73-78.
48. Carrel AL, Myers SE, Whitman BY, Eickhoff J, Allen DB. Long-term growth hormone therapy changes the natural history of body composition and motor function in children with prader-willi syndrome. J Clin Endocrinol Metab 2010;95:1131-1136. Epub 2010 Jan 8
49. Bakker NE, Kuppens RJ, Siemensma EPC, Tummers-de Lind van Wijngaarden RFA, Festen DAM, Bindels-de Heus GC, Bocca G, Haring DA, Hoorweg-Nijman JJ, Houdijk EC, Jira PE, Lunshof L, Odink RJ, Oostdijk W, Rotteveel J, Schroor EJ, Van Alfen AA, Van Leeuwen M, Van Pinxteren-Nagler E, Van Wieringen H, Vreuls RC, Zwaveling-Soonawala N, de Ridder MA, Hokken-Koelega AC. Eight years of growth hormone treatment in children with prader-willi syndrome: maintaining the positive effects. J Clin Endocrinol Metab 2013;98:4013-4022. Epub 2013 Sep 3
50. Carrel AL, Myers SE, Whitman BY, Allen DB. Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: A controlled study. J Pediatr 1999;134:215-221.
51. Angulo MA, Castro-Magana M, Lamerson M, Arguello R, Accacha S, Khan A. Final adult height in children with Prader-Willi syndrome with and without human growth hormone treatment. Am J Med Genet Part A 2007;143A:1456-1461.
52. Menendez AA. Abnormal ventilatory responses in patients with PraderWilli syndrome. Eur J Pediatr 1999;158:941-942.
53. Van Vliet G, Deal CL, Crock PA, Robitaille Y, Oligny LL. Sudden death in growth hormone-treated children with Prader-Willi syndrome. J Pediatr 2004;144:129-131.
54. Eiholzer U, Nordmann Y, l’Allemand D. Fatal outcome of sleep apnoea in PWS during the initial phase of growth hormone treatment. Horm Res Paediatr 2002;58(Suppl 3):24-26.

APA	Dağdeviren Çakır A, Bas F, akın o, siklar z, Özcabı B, berberoglu m, Kardelen A, Bayramoğlu E, Poyrazoglu S, AYDIN H, Törel Ergür A, gökşen d, bolu s, aycan z, Tüysüz B, ERCAN O, Evliyaoğlu O (2021). Clinical Characteristics and Growth Hormone Treatment in Patients with Prader-Willi Syndrome. , 308 - 319. 10.4274/jcrpe.galenos.2021.2020.0228
Chicago	Dağdeviren Çakır Aydilek,Bas Firdevs,akın onur,siklar zeynep,Özcabı Bahar,berberoglu merih,Kardelen Aslı Derya,Bayramoğlu Elvan,Poyrazoglu Sukran,AYDIN HASAN MURAT,Törel Ergür Ayça,gökşen damla,bolu semih,aycan zehra,Tüysüz Beyhan,ERCAN OYA,Evliyaoğlu Olcay Clinical Characteristics and Growth Hormone Treatment in Patients with Prader-Willi Syndrome. (2021): 308 - 319. 10.4274/jcrpe.galenos.2021.2020.0228
MLA	Dağdeviren Çakır Aydilek,Bas Firdevs,akın onur,siklar zeynep,Özcabı Bahar,berberoglu merih,Kardelen Aslı Derya,Bayramoğlu Elvan,Poyrazoglu Sukran,AYDIN HASAN MURAT,Törel Ergür Ayça,gökşen damla,bolu semih,aycan zehra,Tüysüz Beyhan,ERCAN OYA,Evliyaoğlu Olcay Clinical Characteristics and Growth Hormone Treatment in Patients with Prader-Willi Syndrome. , 2021, ss.308 - 319. 10.4274/jcrpe.galenos.2021.2020.0228
AMA	Dağdeviren Çakır A,Bas F,akın o,siklar z,Özcabı B,berberoglu m,Kardelen A,Bayramoğlu E,Poyrazoglu S,AYDIN H,Törel Ergür A,gökşen d,bolu s,aycan z,Tüysüz B,ERCAN O,Evliyaoğlu O Clinical Characteristics and Growth Hormone Treatment in Patients with Prader-Willi Syndrome. . 2021; 308 - 319. 10.4274/jcrpe.galenos.2021.2020.0228
Vancouver	Dağdeviren Çakır A,Bas F,akın o,siklar z,Özcabı B,berberoglu m,Kardelen A,Bayramoğlu E,Poyrazoglu S,AYDIN H,Törel Ergür A,gökşen d,bolu s,aycan z,Tüysüz B,ERCAN O,Evliyaoğlu O Clinical Characteristics and Growth Hormone Treatment in Patients with Prader-Willi Syndrome. . 2021; 308 - 319. 10.4274/jcrpe.galenos.2021.2020.0228
IEEE	Dağdeviren Çakır A,Bas F,akın o,siklar z,Özcabı B,berberoglu m,Kardelen A,Bayramoğlu E,Poyrazoglu S,AYDIN H,Törel Ergür A,gökşen d,bolu s,aycan z,Tüysüz B,ERCAN O,Evliyaoğlu O "Clinical Characteristics and Growth Hormone Treatment in Patients with Prader-Willi Syndrome." , ss.308 - 319, 2021. 10.4274/jcrpe.galenos.2021.2020.0228
ISNAD	Dağdeviren Çakır, Aydilek vd. "Clinical Characteristics and Growth Hormone Treatment in Patients with Prader-Willi Syndrome". (2021), 308-319. https://doi.org/10.4274/jcrpe.galenos.2021.2020.0228

APA	Dağdeviren Çakır A, Bas F, akın o, siklar z, Özcabı B, berberoglu m, Kardelen A, Bayramoğlu E, Poyrazoglu S, AYDIN H, Törel Ergür A, gökşen d, bolu s, aycan z, Tüysüz B, ERCAN O, Evliyaoğlu O (2021). Clinical Characteristics and Growth Hormone Treatment in Patients with Prader-Willi Syndrome. Journal of Clinical Research in Pediatric Endocrinology, 13(3), 308 - 319. 10.4274/jcrpe.galenos.2021.2020.0228
Chicago	Dağdeviren Çakır Aydilek,Bas Firdevs,akın onur,siklar zeynep,Özcabı Bahar,berberoglu merih,Kardelen Aslı Derya,Bayramoğlu Elvan,Poyrazoglu Sukran,AYDIN HASAN MURAT,Törel Ergür Ayça,gökşen damla,bolu semih,aycan zehra,Tüysüz Beyhan,ERCAN OYA,Evliyaoğlu Olcay Clinical Characteristics and Growth Hormone Treatment in Patients with Prader-Willi Syndrome. Journal of Clinical Research in Pediatric Endocrinology 13, no.3 (2021): 308 - 319. 10.4274/jcrpe.galenos.2021.2020.0228
MLA	Dağdeviren Çakır Aydilek,Bas Firdevs,akın onur,siklar zeynep,Özcabı Bahar,berberoglu merih,Kardelen Aslı Derya,Bayramoğlu Elvan,Poyrazoglu Sukran,AYDIN HASAN MURAT,Törel Ergür Ayça,gökşen damla,bolu semih,aycan zehra,Tüysüz Beyhan,ERCAN OYA,Evliyaoğlu Olcay Clinical Characteristics and Growth Hormone Treatment in Patients with Prader-Willi Syndrome. Journal of Clinical Research in Pediatric Endocrinology, vol.13, no.3, 2021, ss.308 - 319. 10.4274/jcrpe.galenos.2021.2020.0228
AMA	Dağdeviren Çakır A,Bas F,akın o,siklar z,Özcabı B,berberoglu m,Kardelen A,Bayramoğlu E,Poyrazoglu S,AYDIN H,Törel Ergür A,gökşen d,bolu s,aycan z,Tüysüz B,ERCAN O,Evliyaoğlu O Clinical Characteristics and Growth Hormone Treatment in Patients with Prader-Willi Syndrome. Journal of Clinical Research in Pediatric Endocrinology. 2021; 13(3): 308 - 319. 10.4274/jcrpe.galenos.2021.2020.0228
Vancouver	Dağdeviren Çakır A,Bas F,akın o,siklar z,Özcabı B,berberoglu m,Kardelen A,Bayramoğlu E,Poyrazoglu S,AYDIN H,Törel Ergür A,gökşen d,bolu s,aycan z,Tüysüz B,ERCAN O,Evliyaoğlu O Clinical Characteristics and Growth Hormone Treatment in Patients with Prader-Willi Syndrome. Journal of Clinical Research in Pediatric Endocrinology. 2021; 13(3): 308 - 319. 10.4274/jcrpe.galenos.2021.2020.0228
IEEE	Dağdeviren Çakır A,Bas F,akın o,siklar z,Özcabı B,berberoglu m,Kardelen A,Bayramoğlu E,Poyrazoglu S,AYDIN H,Törel Ergür A,gökşen d,bolu s,aycan z,Tüysüz B,ERCAN O,Evliyaoğlu O "Clinical Characteristics and Growth Hormone Treatment in Patients with Prader-Willi Syndrome." Journal of Clinical Research in Pediatric Endocrinology, 13, ss.308 - 319, 2021. 10.4274/jcrpe.galenos.2021.2020.0228
ISNAD	Dağdeviren Çakır, Aydilek vd. "Clinical Characteristics and Growth Hormone Treatment in Patients with Prader-Willi Syndrome". Journal of Clinical Research in Pediatric Endocrinology 13/3 (2021), 308-319. https://doi.org/10.4274/jcrpe.galenos.2021.2020.0228